Keywords: antipsychotic pipeline, schizophrenia, bipolar disorder
Pipeline antipsychotic drugs to drive next market evolution
Article | 7 August 2009
Antipsychotic pipeline developers have been in the spotlight in recent weeks with the announcement of the US Food and Drug Administration’s approval of Johnson & Johnson’s Invega Sustenna (paliperidone palmitate), FDA panel backing for Schering-Plough’s Saphris (asenapine) and the end of Lundbeck and Solvay’s collaboration for development of bifeprunox. With a global value of around $22 billion in 2008 - and the leading drug class in the USA - the commercial opportunity for antipsychotics is considerable. According to independent market analyst Datamonitor, the novel and reformulated pipeline atypical antipsychotics will be the engine that drives the growth potential of this developed market forward.
Indication expansion propels growth
Since the introduction of clozapine, the first atypical antipsychotic to treat schizophrenia, the growth of this class has been rapid. Enjoying this article? To continue reading you need to login, take a FREE trial or subscribe.FREE unlimited, no obligation access to The Pharma Letter website for 30 days, normally worth £60!
Sign up in less than 60 seconds...no payment needed
Want to read the full article?
Take a 30 day FREE Trial worth £60
Take a no obligations 30 day trial.
Only one trial per user. Find out more details
Subscribe now
for unlimited access to all articles
Subscriptions are £60 per month, pay as you go.
Find out more details.
Already a subscriber? Click here to log in
- Pfizer acts to stop Mylan marketing generic Chantix; Allergan in $600 million settlement over Botox marketing practices
- PDL BioPharma sues Roche’s Genentech over royalties
- Novartis/NIH-sponsored research yields promising malaria drug candidate
- Indian’s Ranbaxy inaugurates new $30 million drug manufacturing facility in South Africa
- Seattle Genetics gets milestone as Astellas unit moves cancer drug into Ph I
